5WK Stock Overview
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aligos Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.75 |
| 52 Week High | US$1.30 |
| 52 Week Low | US$0.51 |
| Beta | 2.34 |
| 1 Month Change | -15.03% |
| 3 Month Change | 20.32% |
| 1 Year Change | -20.84% |
| 3 Year Change | -96.45% |
| 5 Year Change | n/a |
| Change since IPO | -96.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5WK | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.8% | 0.8% | 1.2% |
| 1Y | -20.8% | -24.4% | 2.0% |
Return vs Industry: 5WK exceeded the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 5WK underperformed the German Market which returned 2% over the past year.
Price Volatility
| 5WK volatility | |
|---|---|
| 5WK Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 4.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 5WK's share price has been volatile over the past 3 months.
Volatility Over Time: 5WK's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 66 | Larry Blatt | www.aligos.com |
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB.
Aligos Therapeutics, Inc. Fundamentals Summary
| 5WK fundamental statistics | |
|---|---|
| Market cap | €55.31m |
| Earnings (TTM) | -€81.96m |
| Revenue (TTM) | €14.52m |
3.8x
P/S Ratio-0.7x
P/E RatioIs 5WK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5WK income statement (TTM) | |
|---|---|
| Revenue | US$15.53m |
| Cost of Revenue | US$73.04m |
| Gross Profit | -US$57.51m |
| Other Expenses | US$30.17m |
| Earnings | -US$87.68m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.16 |
| Gross Margin | -370.35% |
| Net Profit Margin | -564.61% |
| Debt/Equity Ratio | 0% |
How did 5WK perform over the long term?
See historical performance and comparison